Filing Details
- Accession Number:
- 0001209191-21-067347
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-01 19:07:25
- Reporting Period:
- 2021-11-29
- Accepted Time:
- 2021-12-01 19:07:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 920465 | La Jolla Pharmaceutical Co | LJPC | Biological Products, (No Disgnostic Substances) (2836) | 330361285 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1178579 | C Kevin Tang | 4747 Executive Drive, Suite 210 San Diego CA 92121 | Yes | No | Yes | No | |
| 1191935 | Tang Capital Partners Lp | 4747 Executive Drive, Suite 210 San Diego CA 92121 | No | No | Yes | No | |
| 1232621 | Tang Capital Management Llc | 4747 Executive Drive, Suite 210 San Diego CA 92121 | No | No | Yes | No | |
| 1759910 | S Michael Hearne | 4747 Executive Drive, Suite 210 San Diego CA 92121 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-11-29 | 193,403 | $4.10 | 9,855,821 | No | 4 | S | Indirect | By LP |
| Common Stock | Disposition | 2021-11-30 | 6,597 | $3.95 | 9,849,224 | No | 4 | S | Indirect | By LP |
| Common Stock | Disposition | 2021-11-30 | 63,745 | $3.95 | 9,785,479 | No | 4 | S | Indirect | By LP |
| Common Stock | Disposition | 2021-12-01 | 136,255 | $3.76 | 9,649,224 | No | 4 | S | Indirect | By LP |
| Common Stock | Disposition | 2021-12-01 | 41,290 | $3.66 | 9,607,934 | No | 4 | S | Indirect | By LP |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By LP |
| No | 4 | S | Indirect | By LP |
| No | 4 | S | Indirect | By LP |
| No | 4 | S | Indirect | By LP |
| No | 4 | S | Indirect | By LP |
Footnotes
- The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $4,380.25.
- The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.74. TheReporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 and 4 through 7 herein.
- The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP.
- The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.95 to $3.96.
- The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.051.
- The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.89.
- The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.75
Billionaire Hedge Funds
